Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endothelial permeability in uremia.

Steven J Harper1, David O Bates

  • 1Microvascular Research Laboratories, Department of Physiology, University of Bristol, Preclinical Veterinary School, Bristol, United Kingdom. s.harper@bristol.ac.uk

Kidney International. Supplement
|April 16, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ZEB1 Modifies VE-Cadherin Signaling in Lymphatic Endothelial Cells.

Microcirculation (New York, N.Y. : 1994)·2026
Same author

HPV-driven transcriptome and splicing rewiring under SRPK1 inhibition in cervical cancer.

Frontiers in oncology·2026
Same author

The splicing factor kinase SRPK1 is a therapeutic target for peripheral vascular disease.

American journal of physiology. Heart and circulatory physiology·2025
Same author

Angiotensin II type 1 receptor activation induces dorsal horn capillary constriction and pain hypersensitivity.

The journal of pain·2025
Same author

Pharmacological blocking of microfibrillar-associated protein 4 reduces retinal neoangiogenesis and vascular leakage.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

The role of mesenchymal cells in cholangiocarcinoma.

Disease models & mechanisms·2024
Same journal

Effect of kidney disease on glucose handling (including genetic defects).

Kidney international. Supplement·2011
Same journal

Need for better diabetes treatment for improved renal outcome.

Kidney international. Supplement·2011
Same journal

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.

Kidney international. Supplement·2011
Same journal

SGLT2 inhibitors: molecular design and potential differences in effect.

Kidney international. Supplement·2011
Same journal

Glucose handling by the kidney.

Kidney international. Supplement·2011
Same journal

Bone: from a reservoir of minerals to a regulator of energy metabolism.

Kidney international. Supplement·2011
See all related articles

Patients with uremia face a higher cardiovascular disease risk than healthy adults, even before dialysis. Endothelial cell dysfunction and increased transendothelial transport contribute to this accelerated vascular pathology.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Vascular Biology

Background:

  • Patients with long-term uremia exhibit a significantly elevated risk of cardiovascular disease (CVD).
  • This CVD risk surpasses predictions based on traditional vascular risk factors, even prior to dialysis initiation.
  • Accelerated vascular disease in uremia is not fully understood but involves endothelial dysfunction and altered transendothelial transport.

Purpose of the Study:

  • To review the clinical severity of cardiovascular disease in uremia.
  • To examine the role of the vascular endothelium and microvascular permeability in uremic vascular pathology.
  • To present evidence for endothelial dysfunction in both early and dialysis-dependent uremia.

Main Methods:

  • Literature review and synthesis of existing research.

Related Experiment Videos

  • Analysis of in vitro and in vivo studies on endothelial function in uremia.
  • Discussion of microvascular permeability as a functional marker of endothelial health.

    • Main Results:

    • Uremia is associated with profound endothelial cell dysfunction.
    • Increased transendothelial transport of lipids and macromolecules contributes to CVD in uremia.
    • Endothelial dysfunction is a critical factor in the initiation of aggressive cardiovascular pathology in uremic patients.

    Conclusions:

    • Endothelial dysfunction is a central feature of uremia, driving accelerated cardiovascular disease.
    • Understanding endothelial function is crucial for managing CVD risk in uremic populations.
    • Further research into the mechanisms of endothelial dysfunction in uremia is warranted.